Core Viewpoint - Tianfeng Securities maintains a "Buy" rating for He Yu-B (02256), projecting revenue and net profit growth from 2025 to 2027, alongside significant clinical advancements in its drug pipeline [1][2]. Group 1: Financial Projections - The company is expected to achieve revenues of 630 million, 685 million, and 637 million yuan for the years 2025, 2026, and 2027 respectively [1]. - Projected net profits for the same years are 45 million, 70 million, and 102 million yuan [1]. Group 2: Clinical Developments - The clinical research application for the PD-L1 small molecule inhibitor ABSK043 in combination with the KRASG12C inhibitor, Goresiratinib, has been approved by CDE [1]. - The company has established a collaboration agreement with Elysium for the combination therapy [1]. - ABSK141, a KRAS-G12D inhibitor, shows promising oral bioavailability and safety in animal models, with IND approval anticipated in the second half of 2025 [2]. - The Pan-KRAS inhibitor ABSK211 is expected to enter clinical stages in 2026, demonstrating broad inhibitory effects on various KRAS mutations [2]. - The CSF-1R inhibitor ABSK021 (Pimicotinib) plans to submit an NDA to the FDA for TGCT indication in the second half of 2025 [2]. - A bispecific antibody-drug conjugate targeting two pan-cancer targets is projected to achieve preclinical candidate status in early 2026 [2].

Core Viewpoint - Tianfeng Securities maintains a "Buy" rating for the company He Yu-B (02256), projecting revenue and net profit growth from 2025 to 2027, alongside significant clinical research advancements in its drug pipeline [1][2]. Financial Projections - Expected operating revenues for 2025, 2026, and 2027 are CNY 630 million, CNY 685 million, and CNY 637 million respectively [1]. - Projected net profits attributable to the parent company are CNY 45 million, CNY 70 million, and CNY 102 million for the same years [1]. Clinical Research Developments - The clinical research application for the PD-L1 small molecule inhibitor ABSK043 in combination with the KRASG12C inhibitor, Goresiratinib, for treating KRASG12C mutated NSCLC has been approved by CDE [1]. - The company has established a collaboration with Elysium for the combination therapy [1]. Milestone Achievements - ABSK141, a KRAS-G12D inhibitor, shows the best oral bioavailability in animal models and is expected to receive IND approval in the second half of 2025 [2]. - ABSK211, a Pan-KRAS inhibitor, demonstrates broad inhibitory effects on various KRAS mutations and is anticipated to enter clinical stages in 2026 [2]. - The CSF-1R inhibitor ABSK021 (Pimicotinib) is expected to submit an NDA to the FDA for TGCT indication in the second half of 2025 [2]. - A bispecific antibody-drug conjugate targeting two pan-cancer targets is projected to achieve preclinical candidate status in early 2026, aiming to reduce side effects in normal tissues [2].

Core Viewpoint - The recent approval of a new 100mg specification for SKB264 by NMPA is expected to enhance treatment accessibility and convenience for patients with advanced breast cancer and non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Research and Product Development - SKB264's two key clinical studies have been selected for presentation at the 2025 ESMO conference, with the OptiTROP-Lung04 study being featured in the Presidential Symposium, highlighting its potential in treating EGFR-mutant NSCLC [1] - The company anticipates significant revenue growth, projecting revenues of 2.084 billion, 2.876 billion, and 4.663 billion yuan for the years 2025, 2026, and 2027 respectively [1] - SKB264 has received approval for the treatment of EGFR-mutant NSCLC in China and is making progress in earlier lines of treatment, with a New Drug Application (NDA) for 2L NSCLC submitted and prioritized for review [1] Group 2: Efficacy in Rare Mutations and Other Indications - SKB264 has shown promising results in treating rare EGFR mutations, achieving an overall response rate (ORR) of 35.7% and a disease control rate (DCR) of 85.7% in a Phase II study [2] - Ongoing clinical trials for SKB264 in various NSCLC settings are demonstrating superior efficacy compared to other investigational drugs and existing therapies [2] Group 3: Breast Cancer Applications - SKB264 has been approved for use in triple-negative breast cancer (TNBC) and is under review for HR+/HER2- breast cancer, with the NDA based on the successful OptiTROP-Breast02 study [3] - The OptiTROP-Breast02 study has met its primary endpoint, showing significant improvements in progression-free survival (PFS) and a positive trend in overall survival (OS) for HR+/HER2- breast cancer patients [3]

Group 1 - The report from CITIC Securities suggests focusing on investment opportunities in the non-ferrous metal sector, particularly gold, silver, and copper, due to recent price increases driven by various global factors [1] - The surge in gold prices is attributed to the U.S. government shutdown, political uncertainty in Japan, ongoing expectations of interest rate cuts by the Federal Reserve, and continued gold purchases by global central banks [1] - Concerns over the creditworthiness of the U.S. dollar and sovereign debt have led global investors to favor precious metals and cryptocurrencies, further boosting their prices [1] Group 2 - Tianfeng Securities highlights that cyclical stocks may perform well as the economic recovery deepens, with three main investment directions identified: breakthroughs in AI technology, economic recovery leading to stronger performance of cyclical stocks, and the rise of undervalued assets [2] - The report emphasizes that during the early stages of a bull market, funds tend to favor high-growth sectors, while later stages see a focus on core themes, making cyclical stocks attractive due to their low valuations and high beta characteristics [2] Group 3 - CICC's report indicates that A-shares are expected to maintain stable performance post-holiday, with a continuation of the upward trend observed since September 24 of the previous year [3] - The report notes that there has been a steady increase in domestic industrial enterprise profit growth and that the Hong Kong stock market experienced slight gains during the A-share market closure [3]

Core Insights - The company reported a revenue of 1.1 billion yuan for H1 2025, a decrease of 9.97% year-on-year, while the net profit attributable to shareholders increased by 7.56% to 134 million yuan [1] - Cost reduction and efficiency improvement measures are showing positive results, with sales expenses down 31.28% to 294 million yuan and management expenses down 21.58% to 56.75 million yuan [2] - The company signed promotional agreements for Pemabate tablets, which are expected to enhance its product pipeline and competitiveness in the cardiovascular field [3] - Revenue forecasts for 2025-2027 have been adjusted to 2.364 billion, 2.464 billion, and 2.661 billion yuan, while net profit forecasts have been increased to 258 million, 282 million, and 318 million yuan [4] Financial Performance - H1 2025 revenue: 1.1 billion yuan, down 9.97% year-on-year [1] - H1 2025 net profit: 134 million yuan, up 7.56% year-on-year [1] - H1 2025 non-recurring net profit: 107 million yuan, up 13.28% year-on-year [1] Cost Management - Sales expenses decreased from 428 million yuan to 294 million yuan, a reduction of 31.28% [2] - Sales expense ratio fell from 35.06% in H1 2024 to 26.76% [2] - Management expenses decreased from 72.37 million yuan to 56.75 million yuan, a reduction of 21.58% [2] - Asset-liability ratio improved from 31.66% to 28.70% [2] Product Development - The company signed a joint promotion agreement for Pemabate tablets, which have a promising market outlook [3] - Pemabate tablets are the first new selective PPARα modulator approved in China, aimed at lowering triglyceride levels [3] - The promotion of Pemabate tablets is expected to enhance the company's revenue and profit, as well as its academic promotion capabilities [3] Revenue and Profit Forecast - Adjusted revenue forecasts for 2025-2027: 2.364 billion, 2.464 billion, and 2.661 billion yuan [4] - Adjusted net profit forecasts for 2025-2027: 258 million, 282 million, and 318 million yuan [4]

Core Viewpoint - Tianfeng Securities released a report on October 1, adjusting the profit forecast for Xingye Technology (002674.HK) while maintaining a "Buy" rating due to weak domestic sales [1] Financial Forecast - The profit forecast for the years 2025 to 2027 has been slightly adjusted, with expected net profits attributable to the parent company of 140 million, 180 million, and 200 million yuan respectively (previously 150 million, 180 million, and 230 million yuan) [1] - The price-to-earnings (PE) ratios for these years are projected to be 32x, 26x, and 23x respectively [1]

Core Viewpoint - Tianfeng Securities has slightly adjusted the profit forecast for Anta Sports, expecting net profit attributable to shareholders to be 13.6 billion RMB, 15.5 billion RMB, and 17.3 billion RMB for the years 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 18x, 15x, and 14x, maintaining a "Buy" rating Brand Performance - Mature Brand: Anta brand is expected to achieve revenue of 17 billion RMB in H1 2025, a year-on-year increase of 5.4%, accounting for approximately 44% of total revenue, with a gross margin of 54.9% [1] - Growth Brand: FILA brand is projected to generate revenue of 14.2 billion RMB in H1 2025, a year-on-year increase of 8.6%, representing about 37% of total revenue, with a gross margin of 68% [1] - Emerging Brand Portfolio: Other brands (including DESCENTE and KOLON SPORT) are expected to achieve revenue of 7.4 billion RMB in H1 2025, a year-on-year increase of 61.1%, increasing their revenue share from approximately 13% to about 19%, with a gross margin of 73.9% [1] Channel Performance - DTC: Expected revenue of 9.4 billion RMB in H1 2025, a year-on-year increase of 5.3%, accounting for about 56% of total revenue [2] - E-commerce: Anticipated revenue of 6.1 billion RMB in H1 2025, a year-on-year increase of 10.1%, representing approximately 36% of total revenue [2] - Traditional Wholesale and Others: Expected revenue of 1.4 billion RMB in H1 2025, accounting for about 8% of total revenue [3] Strategy and Outlook - The company will continue to implement a "single focus, multi-brand, globalization" strategy in H1 2025, driving growth through dual core brands [4] - Anta brand will deepen its transformation and promote innovation in business models and specialized stores, while FILA will focus on golf and tennis to build a core product matrix [4] - Emerging brands like DESCENTE and KOLON SPORT are expected to maintain rapid growth, with global expansion covering Asia, Europe, and America [4] - The company is enhancing digital integration and initiating AI strategic layouts to drive material research and process innovation [4] - A 3-5 year revitalization plan has been established for the JACK WOLFSKIN brand to reshape its product system [4]

Core Viewpoint - Tianfeng Securities has slightly adjusted the profit forecast for Anta Sports, expecting net profit attributable to shareholders to be 13.6 billion RMB, 15.5 billion RMB, and 17.3 billion RMB for the upcoming years, with corresponding PE ratios of 18x, 15x, and 14x, while maintaining a "Buy" rating [1] Brand Performance - Mature Brand: Anta brand is projected to achieve revenue of 17 billion RMB in H1 2025, a year-on-year increase of 5.4%, accounting for approximately 44% of total revenue, with a gross margin of 54.9% [2] - Growth Brand: FILA brand is expected to generate revenue of 14.2 billion RMB in H1 2025, a year-on-year increase of 8.6%, representing about 37% of total revenue, with a gross margin of 68% [2] - Emerging Brand Portfolio: Other brands, including DESCENTE and KOLON SPORT, are anticipated to achieve revenue of 7.4 billion RMB in H1 2025, a significant year-on-year increase of 61.1%, accounting for about 19% of total revenue, with a gross margin of 73.9% [2] Channel Performance - DTC: Direct-to-Consumer channel is expected to generate revenue of 9.4 billion RMB in H1 2025, a year-on-year increase of 5.3%, making up about 56% of total revenue [3] - E-commerce: Projected revenue of 6.1 billion RMB in H1 2025, a year-on-year increase of 10.1%, accounting for approximately 36% of total revenue [3] - Traditional Wholesale and Others: Expected to achieve revenue of 1.4 billion RMB in H1 2025, representing about 8% of total revenue [4] Strategy and Outlook - The company aims to continue its strategy of "single focus, multiple brands, globalization" in H1 2025, driven by its dual core brands [5] - Anta brand will deepen its transformation and promote innovation, while FILA will focus on golf and tennis to build a core product matrix [5] - The company is advancing its global layout across Asia, Europe, and America, enhancing digital integration and launching AI strategies for material research and process innovation [5] - Sustainability efforts include expanding eco-friendly product lines and improving supply chain responsibility management [5] - The organization is enhancing decision-making flexibility and building a diverse talent pool, with a revival plan for the JACK WOLFSKIN brand over the next 3-5 years [5]

Core Viewpoint - The report from Tianfeng Securities highlights that Dashih Holdings (01405) is a leading player in the pizza sector with strong growth potential, expecting continuous expansion in the Chinese market, improved profitability through store expansion, cost reduction, and headquarters expense dilution [1] Financial Performance - For the first half of 2025 (25H1), the company reported revenue of 2.59 billion yuan, a year-on-year increase of 27.0%, and operating profit at the store level of 380 million yuan, up 28.0% year-on-year [1] - The adjusted net profit for 25H1 was 90 million yuan, reflecting a significant year-on-year growth of 79.6%, with an adjusted net profit margin of 3.5%, up 1.0 percentage points compared to 24H1 [1] Store Expansion and Operations - As of the end of 25H1, the total number of stores reached 1,198, marking a year-on-year growth of 31.1%, with a net addition of 190 stores in 25H1 [2] - The company aims to achieve a target of 300 new stores by 2025, with 43 additional stores opened by August 15, 2025, and 27 more under construction [2] - In terms of same-store sales, there was a decline of 1.0% in 25H1, primarily due to high base effects from strong sales in newly entered markets after December 2022 [2] Revenue by Market - In 25H1, revenue from first-tier cities was 1.08 billion yuan, a year-on-year increase of 7.2%, while revenue from non-first-tier cities reached 1.51 billion yuan, up 46.6%, contributing to 58.2% of total revenue, an increase of 8 percentage points year-on-year [2] Membership Growth - By the end of 25H1, the number of members reached 30.1 million, a year-on-year increase of 55%, with membership contributing to 66.0% of total revenue, up 2.4 percentage points [3] Cost Management - The raw material cost ratio remained stable at 27.3%, while the overall employee compensation expense ratio decreased by 1.1 percentage points to 33.8% [4] - The rental expense ratio was 10.0%, depreciation expense ratio was 4.8%, and advertising and promotion expense ratio was 5.3%, all maintaining relative stability year-on-year [4]

Core Viewpoint - The report from Tianfeng Securities indicates that Dashih Holdings (01405) is a leading player in the pizza sector with strong growth potential, expected to continue expanding in the Chinese market, supported by store expansion, cost reduction, and improved profitability through overhead cost dilution [1] Financial Performance - In the first half of 2025 (25H1), the company reported revenue of 2.59 billion yuan, a year-on-year increase of 27.0%, with operating profit at 380 million yuan, up 28.0% year-on-year, and an operating profit margin of 14.6%, which is an increase of 0.1 percentage points compared to 24H1 and 0.2 percentage points compared to 24H2 [1] - Adjusted net profit for 25H1 was 90 million yuan, representing a year-on-year growth of 79.6%, with an adjusted net profit margin of 3.5%, up 1.0 percentage points year-on-year and stable compared to 24H2 [1] Store Expansion and Operations - The company aims to achieve a store opening target of approximately 98% for the year, with a total of 1,198 stores by the end of 25H1, a year-on-year increase of 31.1%, and a net addition of 190 stores in 25H1 [2] - By August 15, an additional 43 stores were opened, with 27 under construction and 35 signed, aiming for a total of 300 new stores by 2025 [2] - In 25H1, same-store sales declined by 1.0%, primarily due to high base effects from strong sales in newly entered markets after December 2022, while first-tier cities maintained positive same-store growth [2] Revenue by Market - In 25H1, revenue from first-tier markets was 1.08 billion yuan, a year-on-year increase of 7.2%, while revenue from non-first-tier markets reached 1.51 billion yuan, up 46.6%, with the revenue share increasing to 58.2%, an 8 percentage point increase year-on-year, driven by store expansion and strong performance of new stores in newly entered markets [2] Membership Growth - By the end of 25H1, the number of members reached 30.1 million, a year-on-year increase of 55%, with membership contributing to 66.0% of total revenue, up 2.4 percentage points year-on-year [3] Cost Management - In 25H1, the raw material cost ratio was 27.3%, stable year-on-year, while overall employee compensation expense ratio decreased by 1.1 percentage points to 33.8% [4] - Store-level employee cash compensation ratio increased by 0.3 percentage points to 27.7%, due to increased staffing for new market entries, while headquarters employee cash compensation ratio decreased by 0.4 percentage points to 5.1% due to economies of scale [4]